1,471
Views
22
CrossRef citations to date
0
Altmetric
Research Article

The i3+3 design for phase I clinical trials

ORCID Icon, &
Pages 294-304 | Received 11 Jan 2019, Accepted 16 Jun 2019, Published online: 15 Jul 2019

References

  • Guo W, S-J. Wang, S. Yang, H. Lynn, & Y. Ji. 2017. A Bayesian interval dose-finding design addressing Ockham’s razor: MTPI-2. Contemporary Clinical Trials 58:23–33. doi:10.1016/j.cct.2017.04.006.
  • Ivanova, A., N. Flournoy, and Y. Chung. 2007. Cumulative cohort design for dose-finding. Journal of Statistical Planning and Inference 137:2316–2327. doi:10.1016/j.jspi.2006.07.009.
  • Ji Y, P. Liu, Y. Li, B. Nebiyou Bekele. 2010. A modified toxicity probability interval method for dose-finding trials. Clinical Trials (London, England) 7:653–663. doi:10.1177/1740774510382799.
  • Ji, Y., and S. Yang. n.d. On the interval-based dose-finding designs. Preprint at arXiv:1706.03277
  • Ji, Y., and S. J. Wang. 2013. Modified toxicity probability interval design: A safer and more reliable method than the 3 + 3 design for practical phase I trials. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 31:1785–1791. doi:10.1200/JCO.2013.49.0219.
  • Lee, S. M., and Y. K. Cheung. 2011. Calibration of prior variance in the Bayesian continual reassessment method. Statistics in Medicine 30:2081–2089. doi:10.1002/sim.4139.
  • Liu, S., and Y. Yuan. 2015. Bayesian optimal interval designs for phase I clinical trials. J R Stat Soc Ser C 64:507–523. doi:10.1111/rssc.12089.
  • Neuenschwander, B., M. Branson, and T. Gsponer. 2008. Critical aspects of the Bayesian approach to phase I cancer trials. Statistics in Medicine 27:2420–2439. doi:10.1002/sim.3348.
  • O’Quigley, J., M. Pepe, and L. Fisher. 1990. Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics 46:33–48. doi:10.2307/2531628.
  • Paoletti, X., J. O’Quigley, and J. Maccario. 2004. Design efficiency in dose finding studies. Computational Statistics & Data Analysis 45:197–214. doi:10.1016/S0167-9473(02)00323-7.
  • Robertson, T., and W. FT. 1998. Dykstra R: Order restricted statistical inference. New York: John Wiley & Sons.
  • Storer, B. E. 1989. Design and analysis of phase I clinical trials. Biometrics 45:925–937. doi:10.2307/2531693.
  • Tighiouart, M., and A. Rogatko. 2010. Dose finding with escalation with overdose control (EWOC) in cancer clinical trials. Statistical Science: A Review Journal of the Institute of Mathematical Statistics 25:217–226. doi:10.1214/10-STS333.
  • Yang, S., S.-J. Wang, and Y. Ji. 2015. An integrated dose-finding tool for phase I trials in oncology. Contemporary Clinical Trials 45:426–434. doi:10.1016/j.cct.2015.09.019.
  • Zhou, H., Y. Yuan, L. Nie, and S. Accuracy. 2018. Reliability of novel phase I trial designs. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 24:4357–4364.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.